David R. Bauer
Lawyers
Filters
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Intra-Cellular Therapies $14.6 billion acquisition by Johnson & Johnson
We are advising Intra-Cellular Therapies on the transaction
Teoxane proposal to acquire Revance Therapeutics
We are advising Teoxane on the proposed acquisition
Windstream $1.4 billion senior secured first-lien notes offering
The high-yield notes are due 2031
Uranium Energy $300 million at-the-market offering
The shares are listed on NYSE American
Nutanix $862.5 million convertible senior notes offering
The 0.5% convertible senior notes are due 2029
Revolution Medicines $750 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Select Market
ACELYRIN $150 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
Horizon Mutual Holdings debut $600 million senior notes offering
The investment-grade notes are due 2034
GSK strategic alliance with Vesalius Therapeutics
We advised GSK on the transaction